By Iroyin Yoruba Television
The Federal Government has indicated plans to extend by another two years the Presidential Executive Order supporting local pharmaceutical manufacturing, as Nigeria intensifies efforts to strengthen domestic medicine production and reduce dependence on imported pharmaceutical products.
The proposed extension was disclosed amid renewed discussions about the country's pharmaceutical manufacturing capacity, medicine security and the need to build a stronger domestic healthcare supply chain.
The development was announced as stakeholders in Nigeria's pharmaceutical sector continued discussions on how to increase local production, attract investment and improve the country's ability to manufacture essential medicines and pharmaceutical inputs.
The Federal Government's position reflects an increasing emphasis on domestic production as an important component of health-sector resilience. Rather than relying heavily on medicines and pharmaceutical inputs sourced from abroad, policymakers and industry stakeholders are seeking to expand the capacity of Nigerian manufacturers to produce more of the medicines required by the country's large population.
The Minister of State for Health and Social Welfare, Dr Iziaq Adekunle Salako, said strengthening domestic pharmaceutical manufacturing was critical to medicine security, healthcare resilience and economic development.
He spoke during the 8th Nigeria Pharmaceutical Manufacturers Expo in Lagos, where manufacturers, regulators, investors, policymakers and development partners discussed the future of pharmaceutical production in Nigeria.
The expo brought together more than 200 exhibitors and focused on issues including localisation, regional manufacturing, investment, innovation and access to the African market.
The proposed extension of the executive order is significant because policy consistency is one of the issues frequently raised by manufacturers when discussing long-term investment in pharmaceutical production.
Drug manufacturing requires substantial investment in factories, specialised equipment, quality-control systems, skilled personnel and regulatory compliance. Companies considering such investments generally require predictable policies and a clear understanding of the government's direction over several years.
An extension of the executive order would therefore provide additional policy continuity for manufacturers operating in the sector.
The government is also targeting a major increase in the proportion of medicines manufactured locally. Nigeria has set an ambition of producing 70 per cent of its essential medicines domestically by 2030.
Achieving that target would require expansion across several parts of the pharmaceutical value chain rather than simply increasing the number of finished medicines produced inside the country.
The minister identified research and development, innovation, sourcing of active pharmaceutical ingredients and excipients, formulation, manufacturing and quality assurance as areas requiring stronger capacity.
Active pharmaceutical ingredients are particularly important because they are the substances that give medicines their therapeutic effects. If manufacturers remain heavily dependent on imported ingredients, domestic production of finished medicines can still be vulnerable to international supply disruptions, exchange-rate pressures and changes in global prices.
The same applies to pharmaceutical excipients, which are substances used alongside active ingredients to give medicines their appropriate form, stability and other characteristics.
Building local capacity across these areas could therefore make the country's pharmaceutical industry more resilient.
The renewed policy focus also comes against the background of the economic pressures that have affected healthcare and medicine affordability.
Pharmaceutical manufacturers operate within an environment affected by foreign exchange movements, energy costs, imported raw materials, financing costs, logistics expenses and regulatory requirements.
When the cost of producing or importing medicines rises, the pressure can eventually reach patients through higher medicine prices.
Increasing domestic production cannot automatically eliminate those pressures, but policymakers and industry representatives see stronger local capacity as one part of a broader strategy for improving medicine security.
Medicine security means more than simply having pharmaceutical factories. It involves ensuring that essential medicines can be produced, supplied, distributed and made available to patients consistently.
A manufacturing plant may exist, for example, but production can still be interrupted if it cannot obtain necessary raw materials, secure reliable electricity, access foreign currency for specialised inputs or compete with imported products.
This is why the discussions around the executive order are also connected to infrastructure, financing, regulation and industrial policy.
For manufacturers, reliable electricity and other infrastructure are important because pharmaceutical production requires controlled processes and equipment. Power interruptions can increase operating costs and affect production schedules.
Access to affordable financing is also important. Expanding manufacturing capacity requires capital, while pharmaceutical companies must continue investing in quality-control systems, research, regulatory compliance and workforce development.
The government's proposed continuation of the executive order therefore forms part of a much wider challenge: creating an environment in which pharmaceutical manufacturers can invest and remain competitive.
The policy also has a regional dimension.
Nigeria is Africa's most populous country and has one of the continent's largest pharmaceutical markets. A stronger domestic pharmaceutical industry could potentially serve both Nigerian consumers and markets in other African countries.
The pharmaceutical expo therefore placed emphasis on regional manufacturing and access to the African market.
The expansion of regional trade arrangements could create opportunities for Nigerian pharmaceutical companies to sell products beyond the domestic market, provided manufacturers can meet regulatory, quality and pricing requirements in destination countries.
A stronger export-oriented pharmaceutical sector could also contribute to industrial development and employment.
Pharmaceutical manufacturing requires professionals in areas such as pharmacy, chemistry, microbiology, engineering, quality assurance, logistics, regulatory affairs, research and development and production management.
Expanding the sector could consequently create opportunities across several professional and technical fields.
However, increased production must be accompanied by strong quality assurance.
Medicine manufacturing is highly sensitive because poor-quality medicines can directly harm patients. Expanding local production therefore requires effective regulation to ensure that medicines manufactured domestically meet established safety, efficacy and quality requirements.
Regulatory institutions have an important role in maintaining those standards while also ensuring that legitimate manufacturers are not subjected to unnecessary delays.
The government and industry therefore face a balance between encouraging investment and maintaining strict pharmaceutical standards.
The minister's emphasis on research and development also points to another challenge.
Nigeria's pharmaceutical industry needs capacity not only to manufacture medicines developed elsewhere but increasingly to develop products and processes suited to the country's healthcare needs.
Research can help manufacturers develop new formulations, improve production methods and adapt medicines to local requirements.
Greater investment in research could also encourage collaboration between universities, research institutions, pharmaceutical companies and government agencies.
The industry has also been discussing the need to strengthen the supply of pharmaceutical raw materials.
If domestic manufacturers depend almost entirely on overseas suppliers for key ingredients, international events can quickly affect local production.
Shipping disruptions, global shortages, geopolitical tensions, foreign exchange constraints and changes in international commodity prices can all influence the cost and availability of imported inputs.
Developing domestic or regional sources for some pharmaceutical ingredients could reduce exposure to these external shocks.
However, producing pharmaceutical ingredients domestically is technically demanding and may require significant investment. It would therefore likely need a coordinated approach involving government incentives, private-sector investment, research institutions and technical partnerships.
The government's proposed extension of the executive order is consequently being considered within a much larger industrial strategy.
For patients, the ultimate test will be whether these measures improve the availability and affordability of safe and effective medicines.
Policy announcements and investment commitments do not automatically translate into lower medicine prices. The impact depends on whether manufacturers can expand production efficiently, whether competition increases, whether supply chains become more reliable and whether the benefits reach consumers.
The government will also need to monitor the effect of the policy on different categories of medicines.
Some products may be easier to manufacture locally than others. Certain specialised medicines and pharmaceutical ingredients may continue to require imports for some time because domestic production would require advanced technology, specialised facilities or economies of scale that are not yet available.
A realistic strategy therefore requires identifying where Nigeria can rapidly increase domestic capacity while continuing to maintain access to products that are not yet economically or technically viable to produce locally.
The 70 per cent local production target represents an ambitious direction for the industry. Achieving it by 2030 would require sustained implementation rather than a short-term campaign.
Manufacturers would need confidence that government policy will remain stable, while regulators would need sufficient capacity to process applications and supervise production.
Training institutions would also need to produce enough skilled professionals to support an expanding pharmaceutical sector.
Financial institutions and investors would have to be willing to provide long-term capital, while infrastructure providers would need to support industrial production.
The healthcare system itself would benefit from stronger domestic manufacturing if it leads to more reliable supplies of essential medicines.
Hospitals, pharmacies and other healthcare providers depend on predictable medicine availability for effective patient care. Shortages can interrupt treatment and force patients or healthcare providers to search for alternatives.
A more diversified domestic supply base could reduce some of these vulnerabilities.
At the same time, policymakers will need to ensure that local production remains competitive. If domestic medicines are significantly more expensive than comparable imports, simply restricting imports may not deliver the desired result for consumers.
Industrial policy therefore needs to combine incentives for local manufacturers with measures that encourage efficiency, quality and competition.
The pharmaceutical industry's development is also connected to Nigeria's broader economic goals.
A stronger manufacturing sector could reduce the amount of foreign exchange spent importing medicines and pharmaceutical products, while creating opportunities for investment and employment.
If Nigerian companies eventually become competitive exporters, pharmaceutical manufacturing could also become a source of foreign exchange earnings.
The government has therefore framed pharmaceutical manufacturing not only as a healthcare issue but also as an economic and industrial development opportunity.
The proposed two-year extension of the executive order gives policymakers and industry stakeholders additional time to work towards the longer-term objectives.
The period will be important for determining whether the policy can translate into increased factory capacity, stronger local supply chains and greater availability of essential medicines.
The government will also need to work closely with manufacturers to identify barriers that could prevent investment from reaching the production floor.
These barriers could include energy costs, financing, taxation, regulatory processes, infrastructure, access to raw materials and the cost of importing specialised equipment.
Addressing such challenges could determine whether Nigeria's pharmaceutical sector expands at the pace required to meet the 2030 target.
The Federal Government's latest position therefore places pharmaceutical manufacturing firmly within the country's broader health-security agenda.
For Nigeria, medicine security is closely connected to the ability to maintain healthcare services during economic disruptions, global supply shortages and other emergencies.
A stronger domestic pharmaceutical industry would not make Nigeria completely independent of international pharmaceutical supply chains, but it could give the country greater control over an important part of its healthcare system.
The proposed extension of the executive order is now expected to be part of continuing discussions between government and industry stakeholders as Nigeria works towards increasing local pharmaceutical production.
The coming years will determine whether the combination of policy support, private-sector investment, regulatory reform, research and industrial development can deliver the intended expansion.
For patients, the objective remains straightforward: medicines that are safe, available and affordable when they are needed.
For manufacturers, the challenge is to build globally competitive businesses capable of meeting Nigerian demand while eventually serving wider African markets.
And for government, the task is to create the policy and infrastructure environment required for both objectives to be achieved without compromising pharmaceutical quality and patient safety.
Nigeria's pharmaceutical manufacturing drive is therefore entering a period in which implementation will be as important as policy announcements. The proposed extension of the executive order provides additional time, but the success of the strategy will ultimately be measured by increased production capacity, stronger supply chains, sustained investment and improved access to essential medicines.